Key takeaways
- 1The monthly bill dropped from $2,046 to $28 with zero dose changes — only manufacturer and market changed.
- 2The medical emergency in this case was the rationing: halving an anticoagulant dose in atrial fibrillation is stroke-risk, not saving.
- 3One substitution at a time, with monitoring between changes, is what made the transition safe — not the size of the discount.
- 4Telling the prescriber the truth about affordability was the single step that unlocked everything after it.
Case snapshot
- Patient profile
- Composite profile — 58-year-old with type 2 diabetes, hypertension and atrial fibrillation
- Country
- United States
- Condition
- Multiple chronic conditions
- Medicine
- Sitagliptin, apixaban, rosuvastatin, telmisartan
Western cost
$2,046 per month
Reference alternative
$28 per month
Impact
$24,216 per year
On this page
1The situation
The patient in this composite profile is 58 years old, employed, and insured with a high-deductible plan. He takes four medicines daily: a DPP-4 inhibitor for diabetes, an anticoagulant following an atrial fibrillation diagnosis, a statin and an ARB.
None of these are exotic. They are among the most commonly prescribed molecules in the world. Yet until the deductible was met each year, the combined out-of-pocket cost exceeded $2,000 a month.
His response was the response most people have, and it is the dangerous one: he began taking the anticoagulant every other day to make the pack last twice as long, without telling anyone.
2The arithmetic, line by line
At a review appointment he disclosed the rationing. His physician's first action was to restore correct anticoagulant dosing. The second was to work through the list molecule by molecule against same-salt reference pricing.
| Medicine | Before | After | Reduction |
|---|---|---|---|
| Sitagliptin 100 mg, 30 tablets | $550 | $11.00 | 98% |
| Apixaban 5 mg, 60 tablets | $620 | $9.00 | 98.5% |
| Rosuvastatin 10 mg, 30 tablets | $98 | $2.10 | 97.9% |
| Telmisartan 40 mg, 30 tablets | $180 | $1.50 | 99.2% |
| Insulin pen needles and strips | $598 | $4.40 | 99.3% |
| Monthly total | $2,046 | $28.00 | 98.6% |
3How the switch was actually managed
The physician did not switch everything at once. Anticoagulation carries the highest consequence of getting it wrong, so it was handled first and alone, with a clear monitoring plan.
- 1Anticoagulant restored to the correct dose immediately, before any cost discussion continued.
- 2Manufacturer verification for each proposed product — company name, regulatory approvals, batch traceability.
- 3One substitution at a time, with two to three weeks between changes.
- 4Home blood-pressure log and a repeat lipid panel at eight weeks.
- 5HbA1c repeated at three months to confirm glycaemic control held.
- 6A written list kept of every product and batch number in use.
4The outcome
At the six-month review, blood pressure and lipid results were consistent with his previous readings, HbA1c was marginally improved, and — most importantly — he was taking the anticoagulant every single day as prescribed for the first time in over a year.
The clinically significant outcome of this case is not the $24,216 saved. It is that a patient at elevated stroke risk stopped rationing a stroke-prevention medicine.
5About this case study
This is a composite case study. It illustrates a real, documented price pattern using a representative patient profile rather than a specific identifiable individual. Figures are reference ranges, not quotations, and outcomes vary by person, dose and market.
We publish these because abstract percentages do not communicate what a price gap means to a household. A number like '98% cheaper' is forgettable. A monthly bill that drops from an impossible figure to an affordable one is not.
Nothing here is a recommendation to change your own treatment. Every switch described was made with a prescriber's involvement, and yours should be too.
Jivan publishes pricing and educational information only. Do not start, stop, substitute or re-dose any medicine without a licensed physician's approval.
What the Jivan dataset shows
- 59×
- average price gap
- 84%
- of anchors exceed 10×
- 344×
- widest documented gap
Across our full referenced dataset, 476 referenced molecules average a 59× price gap, 84% of them are at least 10× cheaper in India, and the widest documented comparison is Colchicine at 344×. Across the full referenced dataset the median anchor is 84% cheaper, but the four therapy classes in this case (cardiology, endocrinology) sit in the deepest discount band of the catalog.
Computed live from 476 anchors
Frequently asked questions
For off-patent molecules with many competing manufacturers, yes — this reflects documented price differences for identical active ingredients. For on-patent branded therapy the achievable reduction is usually far smaller, and patient assistance programmes matter more.
No. All four active salts, strengths and daily doses stayed exactly the same. Only the manufacturer and the pricing market changed.
Disclosing the rationing. Everything else followed from that conversation, and the rationing itself posed a greater risk than the financial problem.
Sources and further reading
Every factual claim above is traceable to a public primary source. We cite regulators and public health bodies rather than commercial sellers.
- 1Generic Drug FactsU.S. Food & Drug Administration
- 2Health Costs and Prescription Drug ResearchKFF (Kaiser Family Foundation)
- 3National Pharmaceutical Pricing Authority — Price CeilingsGovernment of India, NPPA
- 4MedlinePlus Drug InformationU.S. National Library of Medicine
How this article was made
Written and researched
Pricing Research Editor, Jivan Editorial TeamEditorially reviewed
Editorial Review Board — Jivan
Composite profile assembled from documented price patterns; not a named individual.
Important medical safety notice
Always consult a licensed physician before changing medicine, dose, or brand. Jivan provides educational pricing intelligence and does not replace emergency or diagnostic care.